

Marleen Kok

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1937551/publications.pdf>

Version: 2024-02-01

28
papers

2,485
citations

394421

19
h-index

477307

29
g-index

29
all docs

29
docs citations

29
times ranked

3667
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. <i>Nature Medicine</i> , 2020, 26, 566-576.	30.7	736
2	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	30.7	589
3	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immunology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
4	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
5	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
6	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	12.8	91
7	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.2	90
8	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. <i>Breast Cancer Research</i> , 2019, 21, 90.	5.0	81
9	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. <i>Oncotarget</i> , 2018, 7, e1509820.	4.6	80
10	PKA-induced phosphorylation of ER at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 1-12.	2.5	49
11	Targeting the programmed cell death-1 pathway in breast and ovarian cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2016, 28, 142-147.	2.0	47
12	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	1.6	45
13	Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. <i>Drugs</i> , 2017, 77, 1313-1336.	10.9	39
14	The NF- κ B Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers. <i>Molecular Cancer Research</i> , 2020, 18, 1018-1027.	3.4	31
15	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	5.0	30
16	Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 567-591.	4.1	29
17	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. <i>Modern Pathology</i> , 2018, 31, 1012-1025.	5.5	25
18	Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13. <i>BMC Cancer</i> , 2015, 15, 588.	2.6	24

#	ARTICLE	IF	CITATIONS
19	Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy. <i>European Journal of Cancer</i> , 2020, 127, 240-250.	2.8	21
20	LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer. <i>Nature Cancer</i> , 2022, 3, 355-370.	13.2	21
21	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. <i>Science Translational Medicine</i> , 2021, 13, eabe6201.	12.4	19
22	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	5.2	16
23	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 316.	3.7	16
24	Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-3.	3.0	11
25	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. <i>Cancers</i> , 2021, 13, 4910.	3.7	8
26	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 113531-113542.	1.8	8
27	Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments. <i>Clinical Cancer Research</i> , 2022, 28, 960-971.	7.0	4
28	Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01). <i>Breast Care</i> , 2021, 16, 1-9.	1.4	3